Existing therapeutics have been unable to halt disease progression or extend life in a meaningful way
Cerebain’s novel device approach is supported by research and patient outcomes
Clinical evidence supports the Company’s working approach, that omentum stimulation improves cognitive function in patients with dementia, including Alzheimer’s Disease
Minimally invasive, one-time device implantation will overcome challenges associated with previous omentum stimulation procedures that are highly invasive
Patent-pending technology with broad applicability
Recent scientific breakthroughs regarding the potential identification of gene-specific protein increases prior to on-set of symptoms, could compliment our work
Early diagnosis is key to helping patients maintain quality of life http://www.nia.nih.gov/alzheimers/publication/alzheimers-disease-genetics-fact-sheet
Experienced management and advisory teams with the expertise to move the clinical program forward efficiently and effectively
Patent-pending technology has allowed for the development of a medical device that can
be implanted using a minimally invasive procedure.
Once implanted via what will probably be a same-day surgery procedure, patients may not have to undergo surgery again using this treatment method.
Cerebain has a manufacturing agreement with Sonos Medical, a trusted and reliable medical device supplier.
The Company is now in the process of preparing for initial clinical trials that will most likely occur at multiple medical centers in Europe.
As clinical trials are conducted and variables are put into play (e.g., frequency of stimulation, duration, location, etc.,) we may find that individuals respond differently and require individualized treatment plans. Cerebain’s device can potentially provide this, making our ability to positively impact the lives of as many Alzheimer’s Disease patients as possible.
In 2010 Cerebain Biotech licensed patent-pending technology for an implantable device that stimulates the omentum, and can be adjusted non-invasively to account for a range of factors, including frequency, strength of stimulation and location.
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Technology
Cerebain has a patent-pending device that is implanted in the omentum, a protective layer of skin that protects the abdominal organs. The device is designed to stimulate the omentum in patients with Alzheimer’s Disease. Omental stimulation has been shown to improve cognitive function in patients with dementias, including Alzheimer’s Disease.
Cerebain will evaluate the effect of omental stimulation at different intervals and levels of stimulation to determine the device’s ability to slow, stop or reverse the progression of Alzheimer’s Disease on patients.
Generally described as a protective layer in the abdomen, the omentum covers the intestines, hangs on to the stomach and can be lifted like a flap. While the omentum is not a well-recognized body part, it can play important healing and protective roles for its host.
Protection: The omentum has abundant blood and lymphatic vessels, and can move flexibly throughout the abdomen to protect organs from threat and injury.
Healing: Additionally, it contains the largest supply of stem cells in the adult body. Because of its abundant blood supply, surgeons have long used the omentum to patch internal injuries sustained to other parts of the body.
"Omentum a powerful biological source in regenerative surgery"
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Cerebain Biotech (OTCPK:CBBT) has entered into a letter of intent to purchase the assets of PKG.
With complete in-house vertical integration, PKG provides its customers with all of their product development needs from R&D, design & development, product testing and end of life product support and transitioning.
https://seekingalpha.com/news/3608531-cerebain-biotech-acquire-assets-of-pkg?utm_source=otcmarkets&utm_medium=referral
BEVERLY HILLS, CA / ACCESSWIRE / October 6, 2020 / NMS Consulting, Inc. ("NMS") is pleased to announce that it has been selected as strategic advisor by Cerebain Biotech Cop. (OTCPINK:CBBT) ("Cerebain") for its planned acquisition of PKG, Inc. ("PKG").
COSTA MESA, Calif.--(BUSINESS WIRE)-- Cerebain Biotech Corp. (OTC: CBBT), (the “Company” or “Cerebain”) previously announced, on August 25, 2020, that it had entered into a Letter of Intent to purchase the assets of PKG, Inc. (PKG).
Almir Garibovic, CEO of PKG Inc., stated “After 30 years in business, PKG, Inc. is thrilled that we have entered into a letter of intent to be acquired by Cerebain Biotech Corp. We are excited by this partnership because of our complementary strengths and it will enable us to fulfill our vision and values, while we continue to provide our customers with innovative design, technologies and manufacturing capabilities as never before.”
Eric Clemons, CEO of Cerebain, added "We are committed to evaluating both Companies strategic core competencies to enhance value for our shareholders while maintaining our focus on the continued development of Cerebain’s device for the treatment of Alzheimer’s Disease as well as aggressively managing PKG’s current operations."
About Cerebain Biotech Corp. Cerebain Biotech Corp. (OTC: CBBT) is a development-stage medical device company focused on the creation and clinical development of a minimally invasive implantable device and a synthetic drug solution. The device leverages the clinically observable, positive impact that Omentum stimulation has on cognitive function as related to dementias, and in particular, Alzheimer’s disease. The corporate vision is based on these positive clinical observations. Visit us at www.cerebain.com or connect with us on Twitter and Facebook to learn more.
About PKG Inc. PKG, Inc. was established in 1989 and is a privately held corporation based out of Meridian, ID. PKG, Inc. specializes in contract design, development, and manufacturing of system-level devices with expertise in human-machine interfaces. With experience in medical, aerospace, government, and industrial products, PKG helps to raise your company to the next level by leveraging our skills in engineering and technology integration across your product lines. With a complete in-house vertical integration of expertise, services, manufacturing processes, and technologies, PKG provides our customers with all of their product development and manufacturing needs. In addition to our expertise of system level devices and human machine interfaces, PKG also offers incubation and acceleration services for startup business and entrepreneurs.
COSTA MESA, Calif.--(BUSINESS WIRE)--Cerebain Biotech Corp. (OTC: CBBT), (the “Company” or “Cerebain”) previously announced, on August 25, 2020, that it had entered into a Letter of Intent to purchase the assets of PKG, Inc. (PKG).
“We are committed to evaluating both Companies strategic core competencies to enhance value for our shareholders while maintaining our focus on the continued development of Cerebain’s device for the treatment of Alzheimer’s Disease as well as aggressively managing PKG’s current operations.”
https://abs.twimg.com/errors/logo23x19.png";) -1px center no-repeat; float: left; font-size: 16px; margin: 10px 0px; padding: 3px 3px 3px 28px; border: none; outline: none medium !important;" rel="nofollow ugc">Tweet this
Almir Garibovic, CEO of PKG Inc., stated “After 30 years in business, PKG, Inc. is thrilled that we have entered into a letter of intent to be acquired by Cerebain Biotech Corp. We are excited by this partnership because of our complementary strengths and it will enable us to fulfill our vision and values, while we continue to provide our customers with innovative design, technologies and manufacturing capabilities as never before.”
Eric Clemons, CEO of Cerebain, added "We are committed to evaluating both Companies strategic core competencies to enhance value for our shareholders while maintaining our focus on the continued development of Cerebain’s device for the treatment of Alzheimer’s Disease as well as aggressively managing PKG’s current operations."
PKG, a privately-owned contract manufacturing and engineering company developing high-end medical and aerospace equipment, announced their registration with the FDA as an establishment producing medical personal
protection equipment (PPE), such as surgical masks. PKG also announced the completion of the transfer of its ISO 13485:2016 and ISO 9001:2015 compliance certificates
that encompasses the design, development, and production of its devices.
The TÜV SÜD ISO 13485:2016 certification is for the contract design, development, and manufacture of non-implantable OEM system-level medical systems, subassemblies, and components for the areas of diagnostics,
imaging, patient treatment, monitoring, and surgical devices. This certification is from TÜV SÜD, one of the few organizations recognized as a designated body under the new European Medical Device Regulation (MDR).
It enables PKG to leverage its research, development, and manufacturing strengths for multiple new products addressing novel indications as we advance. TÜV SÜD’s MDR designation
will also ensure the continuity of regulatory compliance and support post-MDR implementation per European Union Directives on medical devices.
PKG Inc.,
MERIDIAN, Idaho, October 5th, 2020
PKG Inc. is pleased to announce a joint agreement with Adventus Venture, a medical device incubator, to finalize development and manufacturing plans for two companies in their portfolio: Allevion Therapeutics and Pressao Medical. PKG Inc. has been in business for over 30 years, developing complex and high-tech products for healthcare, aerospace, industrial, and government markets. In addition to the primary business model that supports Fortune 500 customers, PKG has heavily invested in developing infrastructure for the incubation and acceleration of start-up companies in the medical device sector.
Cerebain Biotech Daily Chart
COSTA MESA, Calif.--(BUSINESS WIRE)-- Cerebain Biotech Corp. (OTC: CBBT), (the “Company” or “Cerebain”) today announces a General Business Update.
Cerebain is in the final stages of its acquisition of PKG, Inc. In combination with the closing of the acquisition of PKG, Cerebain intends to bring the Company’s SEC filings current.
Upon the completion of the acquisition, Cerebain will initiate a review of its overall business and corporate strategic plan. The corporate strategic initiatives to be developed and implemented include, but are not limited to, rebranding and repositioning of the Company’s overall business plan and a comprehensive growth strategy focused on revenue generation through a comprehensive roll-up acquisition strategy of target qualified candidates in select industries.
https://www.otcmarkets.com/stock/CBBT/news/story?e&id=1741596
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Cerebain Biotech Corp OTCMKTS: CBBT) continues to rocket up the charts in recent days after the Company reported it is in the final stages of its acquisition of PKG, Inc. In combination with the closing of the acquisition of PKG, Cerebain intends to bring the Company’s SEC filings current. CBBT has skyrocketed up off its triple zero lows in August to recent highs of $0.025 per share. Microcapdaily first reported on Cerebain and PKG on October 7 when CBBT was trading at $0.003.
Read More here
See the person, not the mask. The first fully transparent, FDA-cleared mask produced in the United States is made possible through a manufacturing partnership between ClearMask LLC, Xometry, and PKG Inc. (Photo: Business Wire)
COSTA MESA, Calif.--(BUSINESS WIRE)--Cerebain Biotech Corp. (OTC: CBBT), today announced that PKG, Inc. is to become the key manufacturer for ClearMask, LLC and Xometry.
“We are proud to help ClearMask fight against the pandemic with a smile on our face that everyone can see. All of us are looking forward to successfully providing innovative accessibility and protection to a diverse population.”
Updated: Nov 20
In addition to facilitating the production of many different types of PPE, Maryland-based Xometry’s on-demand manufacturing marketplace was critical in enabling the production of an innovative transparent mask, ClearMask™, now available in both medical and non-medical versions in the marketplace at https://buy.theclearmask.com/.
Developed by ClearMask LLC, a Maryland-based medical company, the mask is a fully transparent, FDA-approved surgical mask that is essential for medical personnel and doctors who are deaf or hard of hearing and rely on facial expressions, visual cues, and lipreading to communicate. ClearMask blocks infectious particles and droplets through its transparent plastic barrier and has an anti-fog coating.
“ClearMask was approved by the FDA in April 2020, but the company was challenged with finding a manufacturer capable of producing and shipping very high volumes of the masks weekly,” said Greg Paulsen, director of application engineering, Xometry. “We identified a company in our global network of 5,000+ manufacturing suppliers who could produce and assemble millions of masks rapidly and cost effectively. We went beyond the role of supply chain partner and also served as a logistics expert and engineering consultant on this important project.”
Xometry is still managing and coordinating production between the ClearMask team and the supplying facility to ensure production goals are met. Millions of masks have been produced for medical personnel as well as state emergency management agencies, hospitals, essential workers, and different communities in need.
In addition to supporting those who work with deaf and hard of hearing individuals (worldwide there are more than 455 million people who are deaf), ClearMask is important for anyone who benefit from visual facial cues and full facial expressions. Apple, for example, has approved two masks for employee use. One mask is designed by Apple, and the other is ClearMask.
https://www.amtnews.org/post/xometry-helps-clearmask-llc-produce-and-distribute-millions-of-masks
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
OTCShotCaller Saturday, 10/31/20 09:36:12 PM Re: None 0
Post # of 20208
Apparently CBBT is in the process of harnessing the Human Omentum's known capacity for cellular regeneration, an already PROVEN FACT!
What this untapped area of Applied Biotechnology represents qualifies as "Disruptive Technology."
Human Omentum has been repeatedly shown to have the capacity to cause cellular regeneration & repair of various organs in the body including NEURONS!!! I posted several links on this yesterday 10/30/20 of several studies verifying the ability of human omentum to increase cerebral blood flow in brain tissue which in turn favors sustained neuron viability, and theoretically helps prevent the on-set or progress of Alzheimer's symptoms.
One study even showed that if arterial supply to a region of the brain is "tied off" by a surgeon, and then Human Omentum is placed over the area of the brain that the tied off artery supplied, the brain cells in that region of the brain continue to thrive as if the artery supply was never interrupted.
This finding is like something out of a science fiction movie, totally unheard of, totally unexplained, AND it likely represents one of the greatest scientific-medical discovery of modern medicine which CBBT has tapped into with the development of a viable and effective treatment for Alzheimer's.
Know this, Alzheimer's is all about brain cell (neurons) atrophy and death related to decreased blood flow to brain cell tissues with aging. Other mechanisms are involved but this is the primary cause. Nutrients also play a big role in neuron survival and thriving which human omentum highly supports because it's one of the richest nutrient sources in the human body.
Therefore with it's combined effect of causing increased blood flow brain cell tissue in tandem with delivery of high potency nutrients, these forces operating together have the capacity to preserve brain cell function in aging individuals.
This is what CBBT is up to in their Patent development for treating Alzheimer's and as a doctor I believe they are definitely on the right track.
Here's a very brief but major eye-opener video on this topic:
https://www.youtube.com/watch?v=4k7AZlYef_o
Be well and prosper ...
